Key Points
- Anthem insider Joshua Eizen sold 2,826 shares for $11,925.72, reducing his holdings by 1.34% to 207,546 shares. The sale was to cover tax withholding on vested equity awards.
- ANTX shares traded at $4.00, within a 52-week range of $1.00–$7.19. The company reported a quarterly loss of $0.18 per share.
- Analysts’ consensus rating is “Hold,” with a $9.00 price target; two analysts rate the stock a Buy and one a Sell.
-logo-1200x675.jpg?v=20220419083428)
Anthem, Inc. (NASDAQ:ANTX - Get Free Report) insider Joshua Eizen sold 2,826 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $4.22, for a total value of $11,925.72. Following the completion of the sale, the insider owned 207,546 shares of the company's stock, valued at approximately $875,844.12. This trade represents a 1.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Anthem Stock Performance
Shares of NASDAQ ANTX traded up $0.05 during midday trading on Friday, reaching $4.00. 240,356 shares of the company's stock were exchanged, compared to its average volume of 317,730. Anthem, Inc. has a 52-week low of $1.00 and a 52-week high of $7.19. The stock has a market capitalization of $150.96 million, a PE ratio of -3.74 and a beta of -0.93. The business's fifty day moving average price is $4.74 and its two-hundred day moving average price is $4.11.
Anthem (NASDAQ:ANTX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter.
Analysts Set New Price Targets
A number of research firms have recently weighed in on ANTX. Guggenheim assumed coverage on shares of Anthem in a research report on Monday, July 20th. They set a "buy" rating and a $9.00 price target for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Anthem in a research note on Friday, October 2nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $9.00.
Read Our Latest Stock Report on Anthem
Institutional Trading of Anthem
Institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. boosted its holdings in shares of Anthem by 10,422.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 222,225 shares of the company's stock valued at $1,182,000 after buying an additional 220,113 shares during the period. Seven Fleet Capital Management LP raised its stake in Anthem by 4.6% during the second quarter. Seven Fleet Capital Management LP now owns 208,946 shares of the company's stock worth $1,011,000 after acquiring an additional 9,245 shares during the period. Velan Capital Investment Management LP acquired a new position in Anthem in the second quarter valued at approximately $194,000. Citizens Financial Group Inc. RI acquired a new position in Anthem in the second quarter valued at approximately $1,443,000. Finally, Vivo Capital LLC acquired a new position in Anthem in the first quarter valued at approximately $10,785,000. 90.47% of the stock is owned by institutional investors and hedge funds.
Anthem Company Profile
(
Get Free Report)
An2 Therapeutics, Inc is a clinical-stage biopharmaceutical company that traded on the Nasdaq under the symbol ANTX. The company focused on developing novel treatments for serious infectious diseases, with its lead candidate, epetraborole, designed as an oral therapy for pulmonary disease caused by nontuberculous mycobacteria (NTM).
Epetraborole was evaluated in clinical studies involving patients with refractory Mycobacterium avium complex pulmonary disease, a difficult-to-treat infection that primarily affects the lungs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
